Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry - PubMed
3 hours ago
- #risankizumab
- #Crohn's disease
- #real-world evidence
- Risankizumab, an IL-23 inhibitor, was evaluated in a real-world study for difficult-to-treat Crohn's disease.
- The study included 151 patients, with 90.1% having difficult-to-treat disease (failure of ≥2 advanced therapies).
- At week 24, 50% of patients with active disease achieved corticosteroid-free clinical remission.
- In patients with difficult-to-treat disease specifically, 51.8% achieved corticosteroid-free clinical remission at week 24.
- Treatment discontinuation occurred in 14.6% of patients, primarily due to nonresponse.
- Adverse event rates were 35.3 (possibly related) and 16.6 (probably related) per 100 person-years.
- Risankizumab demonstrated favorable effectiveness and safety, supporting its use in difficult-to-treat cases.